Last reviewed · How we verify
Micardis Anlo
Micardis Anlo is a Angiotensin II receptor antagonist Small molecule drug developed by EMS. It is currently in Phase 3 development for Hypertension.
Micardis Anlo is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure.
Micardis Anlo is a small molecule that acts as a type-1 angiotensin II receptor antagonist. It is used to treat hypertension, as indicated by clinical trials studying its efficacy and safety in participants with uncontrolled high blood pressure.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Micardis Anlo |
|---|---|
| Sponsor | EMS |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the angiotensin II receptor, Micardis Anlo reduces the blood pressure by dilating blood vessels and reducing the heart rate. This action also reduces the strain on the heart and kidneys.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Cough
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micardis Anlo CI brief — competitive landscape report
- Micardis Anlo updates RSS · CI watch RSS
- EMS portfolio CI
Frequently asked questions about Micardis Anlo
What is Micardis Anlo?
How does Micardis Anlo work?
What is Micardis Anlo used for?
Who makes Micardis Anlo?
What drug class is Micardis Anlo in?
What development phase is Micardis Anlo in?
What are the side effects of Micardis Anlo?
What does Micardis Anlo target?
Related
- Drug class: All Angiotensin II receptor antagonist drugs
- Target: All drugs targeting AT1 receptor
- Manufacturer: EMS — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing